Cytarabine
Primary Central Nervous System Lymphoma
Explore 71 assets in Primary Central Nervous System Lymphoma →Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
The Lymphoma Academic Research Organisation
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06931652CT.gov Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab | — | Recruiting | — | — | — |
NCT07082868CT.gov A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL) | — | Recruiting | — | — | — |
NCT06830421CT.gov Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients | — | Recruiting | — | — | — |
NCT06946407CT.gov Rituximab, Methotrexate, and Tepadina Induction Followed by Etoposide and Cytarabine Consolidation in Primary Central Nervous System Lymphoma | — | Recruiting | — | — | — |
NCT05518383CT.gov B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 | — | Recruiting | — | — | — |
NCT04083066CT.gov Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma | — | Unknown | — | — | — |
NCT03964090CT.gov Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) | — | Active Not Recruiting | — | — | — |
NCT05274139CT.gov Treatment of Primary CNS Lymphoma ( FTD ) | — | Completed | — | — | — |
NCT03392714CT.gov Bendamustine-based Combination Therapy for PCNSL | — | Unknown | — | — | — |
NCT02203526CT.gov Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma | — | Active Not Recruiting | — | — | — |
Show 7 more trialsShow fewer
NCT01960192CT.gov Treatment of Primary CNS Lymphoma | — | Unknown | — | — | — |
NCT02836158CT.gov Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL | — | Recruiting | — | — | — |
NCT02657785CT.gov Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy | — | Recruiting | — | — | — |
NCT01083342CT.gov High-Dose (HD) Methotrexate (MTX) Induction Chemotherapy Followed by Alternative HD MTX-based and HD Cytarabine-based Combination Consolidation Chemotherapy for Newly Diagnosed Primary CNS Lymphoma; CISL 10-01 Study | — | Completed | — | — | — |
NCT01011920CT.gov Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma | — | Completed | — | — | — |
NCT00647049CT.gov Freiburg ZNS-NHL Study | — | Unknown | — | — | — |
NCT00193973CT.gov Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Primary Central Nervous System Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cytarabine (this asset) | The Lymphoma Academic Research Organisation | Approved | BB · 69 |
| Etoposide | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | P4 | BBB |
| (+)-Vincristine | Ono Pharmaceutical Co., Ltd. | P4 | BBB |
| Adriamycin | Juan P. Alderuccio, MD | P4 | BB |
| Orelabrutinib | The First Affiliated Hospital with Nanjing Medical University | P3 | BB |
| Idarubicin | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | P4 | BB |
| Dexasone | Allison Winter | P4 | BB |
| Cyclophosphamide | Juan P. Alderuccio, MD | P4 | BB |
| Rituximab | Ono Pharmaceutical Co., Ltd. | P4 | BB |
+42 more in the Primary Central Nervous System Lymphoma cohort
Other indications for Cytarabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Promyelocytic Leukemia | — | P4 | A · 82 |
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| Acute Myeloblastic Leukemia With Maturation | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- EtoposideFederal Research Institute of Pediatric Hematology, Oncology and ImmunologyBBB
- (+)-VincristineOno Pharmaceutical Co., Ltd.BBB
- AdriamycinJuan P. Alderuccio, MDBB
- OrelabrutinibThe First Affiliated Hospital with Nanjing Medical UniversityBB
- IdarubicinFederal Research Institute of Pediatric Hematology, Oncology and ImmunologyBB
Citation
Floatz Terminal. Cytarabine in Primary Central Nervous System Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cytarabine-primary-central-nervous-system-lymphoma-33751
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →